SATB2 expression can be reliably used in the differential diagnosis of primary endometrial endometrioid and serous carcinomas as well as primary endocervical adenocarcinomas because nearly all of these tumors are SATB2‐negative. Here, SATB2 is linked to serous adenocarcinoma.